Share this article on:

Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial: Erratum

Alzheimer Disease & Associated Disorders: April–June 2016 - Volume 30 - Issue 2 - p 193
doi: 10.1097/WAD.0000000000000148
Erratum

In the article that appeared on page 1 of the January-March 2016 issue, an error appeared at the end of the first column of page 4. The corrected sentence should read:

Overall, based on visual reads, PET amyloid positivity was highest among mild AD ApoE E4 carriers (90%), followed by prodromal AD ApoE E4 carriers (71%), mild AD noncarriers (58%), and prodromal AD noncarriers (31%).

Back to Top | Article Outline

REFERENCE

Sevigny J, Suhy J, Chiao P, et al.. Amyloid PET Screening for Enrichment of Early-Stage Alzheimer Disease Clinical Trials: Experience in a Phase 1b Clinical Trial. Alzheimer Dis Assoc Disord. 2016;30:1–7.
Copyright © 2016 Wolters Kluwer Health, Inc. All rights reserved